Dienogest

PBAC's latest decision on Dienogest: Recommended with restriction (2024). Considered for Treatment of endometriosis, a chronic hormone-dependent gynaecological condition characterised by dysmenorrhea, pelvic pain, and dyspareunia.

Eligible population

Patients with endometriosis, including those with contraindications to estrogens or long-acting progestogens, and those who do not tolerate other progestogens.

Therapy area

Women's health

Line of therapy

Second-line

Evidence base

RCT

Primary endpoint

Endometriosis associated pelvic pain (assessed by Visual Analogue Scale)

Comparator

norethisterone 5 mg, medroxyprogesterone 10 mg (PBS-listed oral progestogens)

Economic model

Cost-minimisation

ICER note

No economic model was provided; this was a cost-minimisation submission with pricing comparison only.

Similar precedents

• Progesterone
  similarity 0.70
• Relugolix with estradiol and norethisterone acetate
  similarity 0.70
• Estradiol with progesterone
  similarity 0.65
• Estradiol; progesterone; estradiol and progesterone combination
  similarity 0.65
• Medroxyprogesterone acetate
  similarity 0.61
• Etonogestrel with ethinylestradiol
  similarity 0.61